Kai Grosch

Everolimus dosing recommendations for <scp>tuberous sclerosis complex–</scp>associated refractory seizures

David Neal Franz, John A. Lawson, Christian Brandt et al. · Epilepsia · 2018 · 50 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

Miguel R. Abboud, Rodolfo Delfini Cançado, Mariane de Montalembert et al. · Blood · 2023 · 28 citations

Medicine, Pharmacology, Pharmacotherapy +4

Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)

Romain Séchaud, Karen Sinclair, Kai Grosch et al. · Cancer Chemotherapy and Pharmacology · 2022 · 23 citations

Medicine, Pharmacokinetics, Pharmacology +16

Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients

François Pierre Combes, Heidi J. Einolf, Neva Coello et al. · CPT Pharmacometrics & Systems Pharmacology · 2020 · 17 citations · Full text

Pharmacy, Pediatrics, Pharmacology +14

Effect of everolimus on the pharmacokinetics of octreotide long‐acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT‐2 trial

M. Pavel, Carlos Becerra, Kai Grosch et al. · Clinical Pharmacology & Therapeutics · 2016 · 11 citations

Medicine, Oncology, Pharmacology +14